The Australia China Technology Incubator (ACTI), funded by the Department of Industry, Innovation and Science, invites CEOs and Senior Executives of Australian health and medtech companies considering entry into the China market to participate in ACTI’s July Bootcamps.
China is the second largest and fastest growing medtech and pharma market. Over the last few years, this has resulted in increasing investment interest by Chinese medtech and pharma into the Australian healthcare and medical research sector.
The ACTI Bootcamp will tangibly provide CEOs and senior Australian executives of medtech and broader healthcare companies the knowledge to help them develop a successful China business strategy. The two-day workshop will incorporate sessions on developing a market entry strategy; successful partnering approaches; regulatory pathways; distribution and marketing; market risks; common pitfalls; and key success factors for Australian healthcare products, technologies and services into China.
China market specialists Rob Scott, China Representative, AusBiotech and Brendan Mason, former General Manager, Cochlear Greater China, together with other noted speakers from the Australian and Chinese medical industry will deliver the workshop. Rob and Brendan collectively offer more than 20 years in-situ experience managing companies and advising clients in the China medtech and biotech space. By the end of the Bootcamp, companies will be able to develop a high-level China market entry plan and present this to a panel of investors and industry specialists as a key deliverable.
$500 + GST (Start-up Founders)
$950 + GST (Other Attendees)
Contact us to discuss your needs and how we can help. You can drop us an Email email@example.com or call 1 888-271-5063 (US toll free) ♦ 400-842 7017 (Beijing – toll free) ♦ +61 2 9906 2984 (Sydney)